Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Medical Expenditures for Elderly to Decrease 0.4% in FY2004
February 23, 2004
- GEYMS: X-ray Surgery Devices with Electrically-operated C Arm
February 23, 2004
- Medical Institutions' Profits Down, but Industry Profits Up: JMARI Report
February 23, 2004
- BrainLAB: Novalis Body X-Ray Equipment for Radiotherapy
February 23, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 23, 2004
- Notification on Reuse of Implantable Medical Materials
February 23, 2004
- Pfizer Japan to Build Up Ophthalmology Business in Japan
February 23, 2004
- DIAGNOSTIC NEWS IN BRIEF
February 23, 2004
- Takeda's MRs Are Best to Solve Doctors' Problems: Moss Survey
February 23, 2004
- Efficiency of NHI Price System Increased: Dr Yazaki
February 23, 2004
- BUSINESS NEWS IN BRIEF
February 23, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
February 23, 2004
- 1st 3 Qtrs Business Results -1-
February 16, 2004
- DIAGNOSTIC NEWS IN BRIEF
February 16, 2004
- 1st 3 Qtrs Business Results -2-
February 16, 2004
- MEDICAL DEVICE NEWS IN BRIEF
February 16, 2004
- New Drug Organization to Start with 9 Departments Responsible for Application Review
February 16, 2004
- WORLD NEWS IN BRIEF
February 16, 2004
- Chuikyo Talks Break Down on Expanding DPC System to Private Hospitals
February 16, 2004
- AnGes MG, Gene Design to Codevelop 3rd-Generation Decoy Products
February 16, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…